Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

[Issues of oral targeted therapies in daily clinical practice: 5th edition of the congress of pharmacology of anticancer drugs].

Zaibet S, Vauchier C, Khoudour N, Roulleaux Dugage M, Korb-Savoldelli V, Alexandre J, Blanchet B, Goldwasser F, Thomas-Schoemann A, Bellesoeur A.

Bull Cancer. 2018 Nov;105(11):1102-1109. doi: 10.1016/j.bulcan.2018.08.005. Epub 2018 Oct 8. French.

PMID:
30309623
2.

Pharmacokinetic variability of anticoagulants in patients with cancer-associated thrombosis: Clinical consequences.

Bellesoeur A, Thomas-Schoemann A, Allard M, Smadja D, Vidal M, Alexandre J, Goldwasser F, Blanchet B.

Crit Rev Oncol Hematol. 2018 Sep;129:102-112. doi: 10.1016/j.critrevonc.2018.06.015. Epub 2018 Jul 9. Review.

PMID:
30097228
3.

Clinical Pharmacokinetics and Pharmacodynamics of Dabrafenib.

Puszkiel A, Noé G, Bellesoeur A, Kramkimel N, Paludetto MN, Thomas-Schoemann A, Vidal M, Goldwasser F, Chatelut E, Blanchet B.

Clin Pharmacokinet. 2018 Aug 9. doi: 10.1007/s40262-018-0703-0. [Epub ahead of print] Review.

PMID:
30094711
4.

Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients.

Reis R, Labat L, Allard M, Boudou-Rouquette P, Chapron J, Bellesoeur A, Thomas-Schoemann A, Arrondeau J, Giraud F, Alexandre J, Vidal M, Goldwasser F, Blanchet B.

J Pharm Biomed Anal. 2018 Sep 5;158:174-183. doi: 10.1016/j.jpba.2018.05.052. Epub 2018 Jun 1.

PMID:
29883880
5.

Drug monitoring of sunitinib in patients with advanced solid tumors: a monocentric observational French study.

Cabel L, Blanchet B, Thomas-Schoemann A, Huillard O, Bellesoeur A, Cessot A, Giroux J, Boudou-Rouquette P, Coriat R, Vidal M, Saidu NEB, Golmard L, Alexandre J, Goldwasser F.

Fundam Clin Pharmacol. 2018 Feb;32(1):98-107. doi: 10.1111/fcp.12327. Epub 2017 Nov 10.

PMID:
29055166
6.

Individualized Pazopanib Dosing-Letter.

Bellesoeur A, Boudou-Rouquette P, Thomas-Schoemann A, Joly C, Tlemsani C, Vidal M, Goldwasser F, Blanchet B.

Clin Cancer Res. 2017 Oct 15;23(20):6377. doi: 10.1158/1078-0432.CCR-17-1873. No abstract available.

7.

Letter to the editor regarding the paper by Loquai C et al. 'Use of complementary and alternative medicine: a multicenter cross-sectional study in 1089 melanoma patients'.

Fabre E, Thomas-Schoemann A, Blanchet B.

Eur J Cancer. 2017 Nov;85:158-159. doi: 10.1016/j.ejca.2017.07.035. Epub 2017 Sep 3. No abstract available.

PMID:
28877854
8.

ADAM9 expression promotes an aggressive lung adenocarcinoma phenotype.

Kossmann CM, Annereau M, Thomas-Schoemann A, Nicco-Overney C, Chéreau C, Batteux F, Alexandre J, Lemare F.

Tumour Biol. 2017 Jul;39(7):1010428317716077. doi: 10.1177/1010428317716077.

PMID:
28675123
9.

Circulating Tumor DNA Measurement by Picoliter Droplet-Based Digital PCR and Vemurafenib Plasma Concentrations in Patients with Advanced BRAF-Mutated Melanoma.

Garlan F, Blanchet B, Kramkimel N, Puszkiel A, Golmard JL, Noe G, Dupin N, Laurent-Puig P, Vidal M, Taly V, Thomas-Schoemann A.

Target Oncol. 2017 Jun;12(3):365-371. doi: 10.1007/s11523-017-0491-8.

PMID:
28527094
10.

Potential drug-drug interactions with abiraterone in metastatic castration-resistant prostate cancer patients: a prevalence study in France.

Bonnet C, Boudou-Rouquette P, Azoulay-Rutman E, Huillard O, Golmard JL, Carton E, Noé G, Vidal M, Orvoen G, Chah Wakilian A, Villeminey C, Blanchet B, Alexandre J, Goldwasser F, Thomas-Schoemann A.

Cancer Chemother Pharmacol. 2017 May;79(5):1051-1055. doi: 10.1007/s00280-017-3291-z. Epub 2017 Mar 30.

PMID:
28361167
11.

Development and validation of an ELISA method for the quantification of nivolumab in plasma from non-small-cell lung cancer patients.

Puszkiel A, Noé G, Boudou-Rouquette P, Cossec CL, Arrondeau J, Giraud JS, Thomas-Schoemann A, Alexandre J, Vidal M, Goldwasser F, Blanchet B.

J Pharm Biomed Anal. 2017 May 30;139:30-36. doi: 10.1016/j.jpba.2017.02.041. Epub 2017 Feb 24.

PMID:
28260630
12.

Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old.

Bigot F, Boudou-Rouquette P, Arrondeau J, Thomas-Schoemann A, Tlemsani C, Chapron J, Huillard O, Cessot A, Vidal M, Alexandre J, Blanchet B, Goldwasser F.

Invest New Drugs. 2017 Apr;35(2):242-246. doi: 10.1007/s10637-016-0400-5. Epub 2016 Oct 29.

PMID:
27796680
13.

Clinical and kinomic analysis identifies peripheral blood mononuclear cells as a potential pharmacodynamic biomarker in metastatic renal cell carcinoma patients treated with sunitinib.

Noé G, Bellesoeur A, Thomas-Schoemann A, Rangarajan S, Naji F, Puszkiel A, Huillard O, Saidu N, Golmard L, Alexandre J, Goldwasser F, Blanchet B, Vidal M.

Oncotarget. 2016 Oct 11;7(41):67507-67520. doi: 10.18632/oncotarget.11686.

14.

Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review.

Boudou-Rouquette P, Tlemsani C, Blanchet B, Huillard O, Jouinot A, Arrondeau J, Thomas-Schoemann A, Vidal M, Alexandre J, Goldwasser F.

Expert Opin Drug Metab Toxicol. 2016 Dec;12(12):1433-1444. Epub 2016 Aug 24. Review.

PMID:
27556889
15.

Plasma vemurafenib exposure and pre-treatment hepatocyte growth factor level are two factors contributing to the early peripheral lymphocytes depletion in BRAF-mutated melanoma patients.

Puszkiel A, White-Koning M, Dupin N, Kramkimel N, Thomas-Schoemann A, Noé G, Chapuis N, Vidal M, Goldwasser F, Chatelut E, Blanchet B.

Pharmacol Res. 2016 Nov;113(Pt A):709-718. doi: 10.1016/j.phrs.2016.06.032. Epub 2016 Jul 1.

PMID:
27378568
16.

Benefit of therapeutic drug monitoring to disclose pharmacokinetic interaction between sunitinib and calcium channel blocker.

Da Silva F, Thomas-Schoemann A, Huillard O, Goldwasser F, Blanchet B.

Ann Oncol. 2016 Aug;27(8):1651-2. doi: 10.1093/annonc/mdw182. Epub 2016 Apr 26. No abstract available.

PMID:
27117534
17.

[Tyrosine kinase inhibiting the VEGF pathway and elderly people: Tolerance, pre-treatment assessment and side effects management].

Bretagne M, Boudou-Rouquette P, Huillard O, Thomas-Schoemann A, Chahwakilian A, Orvoen G, Arrondeau J, Tlemsani C, Cessot A, Cabanes L, Blanchet B, Coriat R, Alexandre J, Goldwasser F.

Bull Cancer. 2016 Mar;103(3):259-72. doi: 10.1016/j.bulcan.2015.10.020. Epub 2016 Jan 29. Review. French.

PMID:
26832420
18.

Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma.

Kramkimel N, Thomas-Schoemann A, Sakji L, Golmard J, Noe G, Regnier-Rosencher E, Chapuis N, Maubec E, Vidal M, Avril M, Goldwasser F, Mortier L, Dupin N, Blanchet B.

Target Oncol. 2016 Feb;11(1):59-69. doi: 10.1007/s11523-015-0375-8.

PMID:
26208946
19.

A HPLC-fluorescence method for the quantification of abiraterone in plasma from patients with metastatic castration-resistant prostate cancer.

Belleville T, Noé G, Huillard O, Thomas-Schoemann A, Vidal M, Goldwasser F, Alexandre J, Blanchet B.

J Chromatogr B Analyt Technol Biomed Life Sci. 2015 May 1;989:86-90. doi: 10.1016/j.jchromb.2015.03.001. Epub 2015 Mar 9.

PMID:
25813901
20.

Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib.

Tlemsani C, Huillard O, Arrondeau J, Boudou-Rouquette P, Cessot A, Blanchet B, Thomas-Schoemann A, Coriat R, Durand JP, Giroux J, Alexandre J, Goldwasser F.

Expert Opin Drug Metab Toxicol. 2015 May;11(5):785-94. doi: 10.1517/17425255.2015.1030392. Epub 2015 Mar 25. Review.

PMID:
25809423
21.

Sorafenib for patients with differentiated thyroid cancer.

Boudou-Rouquette P, Thomas-Schoemann A, Bellesoeur A, Goldwasser F.

Lancet. 2015 Jan 17;385(9964):227-8. doi: 10.1016/S0140-6736(15)60054-X. No abstract available.

PMID:
25706704
22.

Investigational therapies up to Phase II which target PDGF receptors: potential anti-cancer therapeutics.

Arrondeau J, Huillard O, Tlemsani C, Cessot A, Boudou-Rouquette P, Blanchet B, Thomas-Schoemann A, Vidal M, Tigaud JM, Durand JP, Alexandre J, Goldwasser F.

Expert Opin Investig Drugs. 2015 May;24(5):673-87. doi: 10.1517/13543784.2015.1005736. Epub 2015 Jan 20. Review.

PMID:
25599887
23.

Soluble VEGFR-1: a new biomarker of sorafenib-related hypertension (i.e., sorafenib-related is the compound adjective?).

Thomas-Schoemann A, Blanchet B, Boudou-Rouquette P, Golmard JL, Noé G, Chenevier-Gobeaux C, Lebbe C, Pages C, Durand JP, Alexandre J, Goldwasser F, Guibourdenche J, Vidal M.

J Clin Pharmacol. 2015 Apr;55(4):478-9. doi: 10.1002/jcph.429. Epub 2014 Dec 30. No abstract available.

PMID:
25401221
24.

Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients.

Narjoz C, Cessot A, Thomas-Schoemann A, Golmard JL, Huillard O, Boudou-Rouquette P, Behouche A, Taieb F, Durand JP, Dauphin A, Coriat R, Vidal M, Tod M, Alexandre J, Loriot MA, Goldwasser F, Blanchet B.

Invest New Drugs. 2015 Feb;33(1):257-68. doi: 10.1007/s10637-014-0178-2. Epub 2014 Oct 25.

PMID:
25344452
25.

Sorafenib in thyroid cancer patients: learning from toxicity.

Huillard O, Blanchet B, Boudou-Rouquette P, Thomas-Schoemann A, Wassermann J, Goldwasser F.

Oncologist. 2014 Aug;19(8):e3. doi: 10.1634/theoncologist.2014-0156. Epub 2014 Jul 22. No abstract available.

26.

Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients.

Huillard O, Boissier E, Blanchet B, Thomas-Schoemann A, Cessot A, Boudou-Rouquette P, Durand JP, Coriat R, Giroux J, Alexandre J, Vidal M, Goldwasser F.

Expert Opin Drug Saf. 2014 May;13(5):663-73. doi: 10.1517/14740338.2014.907270. Epub 2014 Apr 3. Review.

PMID:
24693873
27.

Fractionation of daily dose increases the predicted risk of severe sorafenib-induced hand-foot syndrome (HFS).

Hénin E, Blanchet B, Boudou-Rouquette P, Thomas-Schoemann A, Freyer G, Vidal M, Goldwasser F, Tod M.

Cancer Chemother Pharmacol. 2014 Feb;73(2):287-97. doi: 10.1007/s00280-013-2352-1. Epub 2013 Nov 20.

PMID:
24253177
28.

Drug interactions with solid tumour-targeted therapies.

Thomas-Schoemann A, Blanchet B, Bardin C, Noé G, Boudou-Rouquette P, Vidal M, Goldwasser F.

Crit Rev Oncol Hematol. 2014 Jan;89(1):179-96. doi: 10.1016/j.critrevonc.2013.08.007. Epub 2013 Aug 28. Review.

PMID:
24041628
29.

A new strategy to target regulatory T cells in solid tumors.

Thomas-Schoemann A, Batteux F, Alexandre J.

Oncoimmunology. 2013 Mar 1;2(3):e23338.

30.

An HPLC-UV method for the simultaneous quantification of vemurafenib and erlotinib in plasma from cancer patients.

Zhen Y, Thomas-Schoemann A, Sakji L, Boudou-Rouquette P, Dupin N, Mortier L, Vidal M, Goldwasser F, Blanchet B.

J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Jun 1;928:93-7. doi: 10.1016/j.jchromb.2013.03.017. Epub 2013 Mar 25.

PMID:
23602929
31.

Arsenic trioxide exerts antitumor activity through regulatory T cell depletion mediated by oxidative stress in a murine model of colon cancer.

Thomas-Schoemann A, Batteux F, Mongaret C, Nicco C, Chéreau C, Annereau M, Dauphin A, Goldwasser F, Weill B, Lemare F, Alexandre J.

J Immunol. 2012 Dec 1;189(11):5171-7. doi: 10.4049/jimmunol.1103094. Epub 2012 Oct 26.

32.

Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study.

Boudou-Rouquette P, Narjoz C, Golmard JL, Thomas-Schoemann A, Mir O, Taieb F, Durand JP, Coriat R, Dauphin A, Vidal M, Tod M, Loriot MA, Goldwasser F, Blanchet B.

PLoS One. 2012;7(8):e42875. doi: 10.1371/journal.pone.0042875. Epub 2012 Aug 13.

33.

Functional and clinical evidence of the influence of sorafenib binding to albumin on sorafenib disposition in adult cancer patients.

Tod M, Mir O, Bancelin N, Coriat R, Thomas-Schoemann A, Taieb F, Boudou-Rouquette P, Ropert S, Michels J, Abbas H, Durand JP, Dauphin A, Vidal M, Goldwasser F, Blanchet B.

Pharm Res. 2011 Dec;28(12):3199-207. doi: 10.1007/s11095-011-0499-1. Epub 2011 Jun 21.

PMID:
21691893
34.

[Use of antioxidant and other complementary medicine by patients treated by antitumor chemotherapy: a prospective study].

Thomas-Schoemann A, Alexandre J, Mongaret C, Azibi S, Dauphin A, Goldwasser F, Lemare F.

Bull Cancer. 2011 Jun;98(6):645-53. doi: 10.1684/bdc.2011.1375. French.

35.

Individual dosing regimen of mycophenolate mofetil in lupus patients: comment on the article by Zahr et al.

Thomas-Schoemann A, Batteux F, Weill B, Dauphin A, Blanchet B.

Arthritis Rheum. 2011 Jun;63(6):1760-1; author reply 1761-2. doi: 10.1002/art.30330. No abstract available.

36.

Bystander effect of vinorelbine alters antitumor immune response.

Thomas-Schoemann A, Lemare F, Mongaret C, Bermudez E, Chéreau C, Nicco C, Dauphin A, Weill B, Goldwasser F, Batteux F, Alexandre J.

Int J Cancer. 2011 Sep 15;129(6):1511-8. doi: 10.1002/ijc.25813. Epub 2011 Apr 1.

37.

Tumor invasion induced by oxidative stress is dependent on membrane ADAM 9 protein and its secreted form.

Mongaret C, Alexandre J, Thomas-Schoemann A, Bermudez E, Chéreau C, Nicco C, Goldwasser F, Weill B, Batteux F, Lemare F.

Int J Cancer. 2011 Aug 15;129(4):791-8. doi: 10.1002/ijc.25746. Epub 2010 Dec 9.

Supplemental Content

Loading ...
Support Center